succinobucol has been researched along with Vascular Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kunsch, C; Malinin, A; Qiu, FH; Scott, R; Serebruany, V; Xu, XC | 1 |
| Malinin, A; Scott, R; Serebruany, V | 1 |
1 trial(s) available for succinobucol and Vascular Diseases
| Article | Year |
|---|---|
Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy.
Topics: Adolescent; Adult; Aged; Biomarkers; Cells, Cultured; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Humans; Lipoproteins; Male; Middle Aged; Probucol; Risk Factors; Thromboxanes; Vascular Diseases; Young Adult | 2009 |
1 other study(ies) available for succinobucol and Vascular Diseases
| Article | Year |
|---|---|
The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease.
Topics: Adult; Antigens, CD; Antioxidants; Baltimore; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Female; Flow Cytometry; Humans; Linear Models; Male; Middle Aged; Platelet Aggregation; Platelet Membrane Glycoproteins; Probucol; Receptors, Cell Surface; Risk Factors; Vascular Diseases | 2006 |